-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 18, the Shanghai Municipal Supervision Bureau announced that, under the jurisdiction of the State Administration of Municipal Supervision, the Shanghai Municipal Administration of Market Supervision has recently abused its market dominance against a pharmaceutical company in Nanjing and implemented the sale of pristine chloride at an unfairly high price.
Administrative penalties were imposed on monopolistic behaviors of raw materials and additional unreasonable trading conditions, with a total fines of RMB 6,583,700
.
The main purpose of the raw material of pristine chloride is to combine with the phosphoryl group in phosphorylated cholinesterase in the body to form a non-toxic substance that is excreted in the urine and restore cholinesterase activity.
It is a kind of organophosphorus pesticide poisoning.
Rescue medicine
.
Among them, the raw material of pristine chloride is the basic raw material for the production of pristine chloride injection
.
It is understood that pralidoxime chloride injection is a national medical insurance Class A drug and is a clinically necessary drug.
Once an API company sells the drug at a high price, it will easily cause a price surge, which will increase the production cost of downstream pharmaceutical companies and affect downstream drugs.
The stable production of the company will even harm the interests of patients
.
Therefore, it is very necessary to punish the monopoly in the field of APIs in a timely manner
.
It is worth mentioning that this is at least the 5th company that has imposed fines due to the monopoly of APIs during the year
.
In January of this year, Simcere Pharmaceutical was fined 100.
7 million yuan by the State Administration for Market Regulation for abusing its dominant position in the sales of Batroxobin concentrate in China; Enterprises have imposed administrative penalties for the implementation of monopoly agreements, with a total of 764 million yuan fined and confiscated
.
Also in April, a Tianjin pharmaceutical factory was suspected of monopolizing fluocinolone acetoacetate APIs and was ordered by the Tianjin Municipal Commission of Market Supervision to stop its illegal activities, confiscated the company's illegal income of RMB 8,897,800, and imposed a fine of 4% of its sales in 2019.
35,124,700 yuan, and the above fines and confiscated amounts totaled 44,022,600 yuan
.
Immediately in October of the second half of the year, a pharmaceutical company in Shangqiu City abused its dominant position in the phenol bulk drug sales market in China for selling products at unfairly high prices and was fined RMB 11.
044 million by the State Administration of Market Supervision.
.
APIs have become the "hardest hit area" monopolized by pharmaceutical companies, and monopolistic behaviors have been repeatedly banned. .
According to incomplete statistics, from 2016 to the present, a total of nearly 20 companies have been punished for monopolistic behavior of APIs
.
In order to say no to monopolistic behavior in the field of APIs and guide operators to operate in compliance with laws and regulations, relevant departments have also taken continuous actions in recent years
.
For example, in 2020, the State Administration for Market Regulation drafted the "Guidelines for Anti-Monopoly in the Field of APIs (Draft for Comment)", which defines and regulates monopolistic violations in the field of APIs, aiming to promote the healthy development of the API industry and maintain APIs.
Market competition order, protection of consumer interests and social public interests, prevention and suppression of monopolistic activities in the field of APIs, and promotion of scientific and effective anti-monopoly supervision
.
On November 18, the National Anti-Monopoly Bureau was formally established.
On the same day, the anti-monopoly guidelines in the field of APIs were also released, which clarified the basic principles, ideas and methods of anti-monopoly supervision of APIs, and refined the standards for determining monopolistic behavior.
.
This also means that the supervision of APIs continues to upgrade
.
Under the stricter regulation of the industry, API companies still need to regulate their operations, and do not "step on thunder" for immediate benefits in order to go further
.
Administrative penalties were imposed on monopolistic behaviors of raw materials and additional unreasonable trading conditions, with a total fines of RMB 6,583,700
.
The main purpose of the raw material of pristine chloride is to combine with the phosphoryl group in phosphorylated cholinesterase in the body to form a non-toxic substance that is excreted in the urine and restore cholinesterase activity.
It is a kind of organophosphorus pesticide poisoning.
Rescue medicine
.
Among them, the raw material of pristine chloride is the basic raw material for the production of pristine chloride injection
.
It is understood that pralidoxime chloride injection is a national medical insurance Class A drug and is a clinically necessary drug.
Once an API company sells the drug at a high price, it will easily cause a price surge, which will increase the production cost of downstream pharmaceutical companies and affect downstream drugs.
The stable production of the company will even harm the interests of patients
.
Therefore, it is very necessary to punish the monopoly in the field of APIs in a timely manner
.
It is worth mentioning that this is at least the 5th company that has imposed fines due to the monopoly of APIs during the year
.
In January of this year, Simcere Pharmaceutical was fined 100.
7 million yuan by the State Administration for Market Regulation for abusing its dominant position in the sales of Batroxobin concentrate in China; Enterprises have imposed administrative penalties for the implementation of monopoly agreements, with a total of 764 million yuan fined and confiscated
.
Also in April, a Tianjin pharmaceutical factory was suspected of monopolizing fluocinolone acetoacetate APIs and was ordered by the Tianjin Municipal Commission of Market Supervision to stop its illegal activities, confiscated the company's illegal income of RMB 8,897,800, and imposed a fine of 4% of its sales in 2019.
35,124,700 yuan, and the above fines and confiscated amounts totaled 44,022,600 yuan
.
Immediately in October of the second half of the year, a pharmaceutical company in Shangqiu City abused its dominant position in the phenol bulk drug sales market in China for selling products at unfairly high prices and was fined RMB 11.
044 million by the State Administration of Market Supervision.
.
APIs have become the "hardest hit area" monopolized by pharmaceutical companies, and monopolistic behaviors have been repeatedly banned. .
According to incomplete statistics, from 2016 to the present, a total of nearly 20 companies have been punished for monopolistic behavior of APIs
.
In order to say no to monopolistic behavior in the field of APIs and guide operators to operate in compliance with laws and regulations, relevant departments have also taken continuous actions in recent years
.
For example, in 2020, the State Administration for Market Regulation drafted the "Guidelines for Anti-Monopoly in the Field of APIs (Draft for Comment)", which defines and regulates monopolistic violations in the field of APIs, aiming to promote the healthy development of the API industry and maintain APIs.
Market competition order, protection of consumer interests and social public interests, prevention and suppression of monopolistic activities in the field of APIs, and promotion of scientific and effective anti-monopoly supervision
.
On November 18, the National Anti-Monopoly Bureau was formally established.
On the same day, the anti-monopoly guidelines in the field of APIs were also released, which clarified the basic principles, ideas and methods of anti-monopoly supervision of APIs, and refined the standards for determining monopolistic behavior.
.
This also means that the supervision of APIs continues to upgrade
.
Under the stricter regulation of the industry, API companies still need to regulate their operations, and do not "step on thunder" for immediate benefits in order to go further
.
